Organization
Elicio Therapeutics
2 clinical trials
1 abstract
Clinical trial
First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-01-26
Clinical trial
First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid TumorsStatus: Recruiting, Estimated PCD: 2026-11-01
Abstract
AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, University of California at Los Angeles, Massachusetts General Hospital, University of Iowa Hospitals & Clinics,